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driving further increases in both diseases yet holding the tantalizing 
possibility for prevention of both.
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Summary: Noninfectious uveitis is a sight-threatening, immune-
mediated intraocular inflammatory disorder. Posterior uveitis can 
involve the retina, choroid, vitreous, and optic nerve. Uveitis can 
result from heterogeneous numerous etiologies, including infectious, 
autoimmune causes, and tumoral-mimicking uveitis. Infectious and 
tumoral causes need specific treatment. Primary or secondary autoim-
mune disorders of posterior ocular segment require anti-inflamma-
tory treatment to prevent from visual loss.
Uveitis is responsible for ~10% of the visual handicap.
Immunodepressive treatment is required in sight-threatening 
noninfectious posterior uveitis. Nowadays, corticosteroid therapy 
remains the first-line conventional treatment for active, noninfec-
tious uveitis. Corticosteroids could be administered by peri or intra-
ocular injection, using intravitreal implant, or systemically. The limit 
od intra-ocular steroid are side effects as secondary glaucoma and 
a short time therapeutic activity needing re-injection or bilateral 
injection for bilateral chronic uveitis. Therefore, posterior chronic 
bilateral uveitis is still nowadays treated with an oral steroid such 
as prednisone. If the daily dose threshold is greater than ~0.2 mg/
kg/d of prednisone, a combination of immunosuppressive or immu-
nomodulator drugs is indicated, both for their own immunosuppres-
sive and steroid-sparing capabilities.
Immunosupressive agents, conventionally used in its indication, can 
be categorized into 3 main classes: T-cell inhibitors (cyclosporine, tac-
rolimus), antimetabolites (azathioprine, methotrexate, mycophenolate 
mofetil, leflunomide), and alkylating agents (cyclophosphamide, chloram-
bucil). All had been shown efficient in severe uveitis. Side effects include 
increased risk of infection, hematologic toxicity, sterility, and secondary 
malignancy. Moreover, immunosuppressive drugs can exhibit selective 
tissue toxicity as renal toxicity induced by cyclosporine treatment.
The risk of severe side effects of immunosuppressive drugs has 
led to the evaluation of the therapeutic benefit of immunomodulator 
drugs such as polyclonal antibodies and interferon alpha. The thera-
peutic benefit of INFa in Behcet’s disease was recently documented in 
a meta-analysis of both systemic disease control and uveitis control. 
The frequency of ocular attacks was significantly reduced compared 
with the pretreatment observation period, and there was a significant 
steroid-sparing effect. A randomized prospective study has been done 
using 3 arms - with only steroids systemic therapy - with only inf 
alpha systemic therapy – under only observation, for 4 months, in the 
chronic noninfectious posterior uveitis associated to macular edema. 
The main criteria was the central foveal thickness, an objective, repro-
ductible parameter measured through optical coherence tomography, 
a noninvasive tool. The results will be presented in the conference.
Trial Randomized multicentric trial. Code number P051032. 
Biomedical research Phase II with individual direct benefit.. 
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